Fish Recall Update for 3 States as FDA Sets Highest Risk Level
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Food inspectors have designated the highest risk level to a recall of fish feared to be contaminated with bacterium that causes a rare, life-threatening condition.
P. East Trading Corp. voluntarily recalled 81 cases of Salted Smoked Split Herring—or kippers—distributed across retail locations in New York, New Jersey and Connecticut because of the potential for contamination with clostridium botulinum, the bacterium responsible for botulism, the U.S. Food and Drug Administration (FDA) announced in a company press release on June 10.
The FDA classified the recall as Class I, its highest risk level for food recalls, on Tuesday.
The fish, distributed under the description "Salted Smoked Split Herring," was sold in 18-pound wooden boxes and was often repackaged.
No illnesses connected to the recall have been reported as of June 10, the company said.
Newsweek contacted P. East Trading Corp. for comment on Wednesday.
Stock picture of smoked herring fish fillet on wooden board with herbs.
Stock picture of smoked herring fish fillet on wooden board with herbs.
Getty Images
Why It Matters
The recall raised health concerns in the three states because uneviscerated fish over five inches in length are known to be susceptible to contamination with clostridium botulinum spores, posing a potentially fatal health risk to consumers.
Botulism can cause severe symptoms, including paralysis and death, and toxins may be present even if the product appears normal, according to the FDA.
What To Know
"The product was likely to be repacked by these retail locations in deli-style or other retail packaging," the June 10 recall notice said.
A list of locations that received and potentially sold the recalled products can be found here.
The affected product carries code Lot 1PRC5073 and was manufactured by Sea Star Seafood Ltd. of Canada, the FDA's announcement said.
P. East Trading Corp., located in the Bronx, New York, issued the voluntary recall following analysis by New York State Food Laboratory personnel, who said the fish was not properly eviscerated. FDA documentation says that sale of uneviscerated fish longer than 5 inches is especially risky because of the concentration of C. botulinum spores in fish viscera. The recall covers 81 cases in total, the FDA said.
The FDA classified the recall as Class I, meaning there is a reasonable probability that eating the product will cause health problems or death (FDA Import Alert #16-74). Consumers are advised not to eat the fish, even if it does not look or smell spoiled, because toxins produced by C. botulinum are undetectable via appearance or taste.
The product was sold through a wide network of supermarket and specialty food retailers in the tri-state area. Locations that received the product include multiple outlets in major cities and suburban communities, such as Pioneer Supermarket (Newark, New Jersey), Joe's Market #3 (Irvington, New Jersey), Keyfood Supermarket (Laurelton, New York), Happy Fruit Market (Teaneck, New Jersey), Food Bazaar Supermarkets, C Town Supermarkets, Ideal Food Basket and dozens more.
Botulism Symptoms
Symptoms of botulism include general weakness, dizziness, double vision, speech or swallowing difficulties, muscle weakness, abdominal distension and constipation. Immediate medical attention is urged for people who experience such symptoms following fish consumption.
The FDA maintains ongoing import alerts against uneviscerated or partially eviscerated fish because of the high risk for botulism outbreaks. Historical data show that improperly processed fish have caused multiple severe and sometimes fatal outbreaks in the U.S. and globally, notably among immigrants and ethnic communities with traditional fish preservation methods.
Proper evisceration and processing are mandated in the U.S. to control C. botulinum, and the FDA requires manufacturers to maintain appropriate Hazard Analysis and Critical Control Point plans to verify products' safety before releasing them to the American market.
What Happens Next
Consumers who bought the fish are urged to return the product to the place of purchase for a full refund. The company provided a direct contact—Jay Hong, office manager, at (718) 991-6070 or peastl@gmail.com—for further information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
18 minutes ago
- Newsweek
Opioids: Parasitic Worm Discovery Could Lead to Safer Painkillers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The evolutionary trick of parasitic worm that sneakily burrows into the skin of its victims could provide new alternatives to opioid-based pain treatments. Opioids are currently used to treat moderate to severe pain, as well coughing and diarrhea. Although they can provide effective relief, long-term use can also lead to dependence, with negative physical and mental health consequences. Researchers discovered that the worm—Schistosoma mansoni—suppresses neurons in the skin to evade detection in a mechanism likely developed to enhance its own survival. The molecules responsible for this suppression of sensation could help in the development of new painkillers, according to the team at the Tulane School of Medicine. Schistosomiasis is a parasitic infection caused by helminths, a type of worm known to survive in their mammal hosts for many years. Their larvae can infest freshwater bodies like lakes, ponds and rivers—infecting people who, for example, swim, fish or wash clothes in the water. "While bacteria often cause painful cutaneous reactions, host skin invasion by the human parasitic helminth Schistosoma mansoni often goes unnoticed," the researchers wrote in their paper. Medical microscopy showing parasite. Medical microscopy showing parasite. defun/Getty Images S. mansoni often evades detection by the immune system, unlike other bacteria or parasites that cause pain, itching or rashes—a feat the team set out to investigate. After conducting experiments on mice, the researchers found that S. mansoni produces molecules that suppress the activity of TRPV1+, a protein used to send signals that the brain interprets as heat, itching or pain. As part of the pain-sensing process in sensory neurons, TRPV1+ regulates immune responses in scenarios including allergy, autoimmunity, cancer, infection and even hair growth, the researchers explained. It is likely the parasitic worm evolved its ability to block TRPV1+ because it enhance its survival, the researchers said. "If we identify and isolate the molecules used by helminths to block TRPV1+ activation, it may present a novel alternative to current opioid-based treatments for reducing pain," said paper author and immunologist professor De'Broski R. Herbert| in a statement. "The molecules that block TRPV1+ could also be developed into therapeutics that reduce disease severity for individuals suffering from painful inflammatory conditions." Open spillage bottle of opioid pain killing tablets. Open spillage bottle of opioid pain killing tablets. BackyardProduction/Getty Images The study also revealed that TRPV1+ is necessary for initiating host protection against S. mansoni. Activation of the protein leads to rapid mobilization of immune cells, including gd T cells, monocytes and neutrophils, which induce inflammation. This inflammation, the researchers explained, plays a crucial role in host resistance to the larval entry into the skin. These findings highlight the importance of neurons that sense pain and itching in successful immune responses. "Identifying the molecules in S. mansoni that block TRPV1+ could inform preventive treatments for schistosomiasis. We envision a topical agent which activates TRPV1+ to prevent infection from contaminated water for individuals at risk of acquiring S. mansoni," said Herbert. In the study, mice were infected with S. mansoni and evaluated for their sensitivity to pain as well as the role of TRPV1+ in preventing infection. "S. mansoni infection significantly reduced thermal pain sensitivity evoked by TRPV1+ neurons. Consistently, isolated skin sensory neurons from infected mice had significantly reduced calcium influx and neuropeptide [chemical messenger] release in response to the TRPV1 agonist capsaicin [an irritant for humans and mammals] compared to neurons from naïve controls," the study authors wrote. "Using gain-and loss-of-function approaches to test whether TRPV1+ neurons initiate host-protective responses revealed that TRPV1+ neurons limit S. mansoni skin entry and migration into the pulmonary tract." The researchers are now planning to identify the nature of the secreted or surface-associated helminth molecules that are responsible for blocking TRPV1+ activity and specific gd T cell subsets that are responsible for immune responses. They also seek to further understand the neurons that helminths have evolved to suppress. Newsweek has reached out to the researchers for additional comment. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about opioids? Let us know via health@ Reference Inclan-Rico, J. M., Stephenson, A., Napuri, C. M., Rossi, H. L., Hung, L.-Y., Pastore, C. F., Luo, W., & Herbert, D. R. (2025). TRPV1+ neurons promote cutaneous immunity against Schistosoma mansoni. The Journal of Immunology.
Newsweek
an hour ago
- Newsweek
Diabetes Warning Issued Over Insulin Pump Error
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A medical device manufacturer has issued an urgent correction for select insulin pumps due to a possible error that could result in insulin not being delivered, the U.S. Food and Drug Administration (FDA) announced. Tandem Diabetes Care, Inc., based in California, said the error appears as a Malfunction 16 alarm to users, and may stop insulin delivery. It can also halt communication between the insulin pump and the continuous glucose monitoring (CGM) device. Newsweek contacted Tandem Diabetes Care, Inc. for comment by email outside of regular working hours. Stock image. Tandem Diabetes Care, Inc. has issued a correction for select insulin pumps due to a possible error that could result in insulin not being delivered. Stock image. Tandem Diabetes Care, Inc. has issued a correction for select insulin pumps due to a possible error that could result in insulin not being delivered. Jens Kalaene/picture-alliance/dpa/AP Why It Matters The FDA said that if the error is not addressed it could lead to hyperglycemia - high blood sugar - in users due to insulin not being delivered. "In severe cases of hyperglycemia, the user may require hospitalization or intervention from a medical professional," it said. Hyperglycemia symptoms include extreme thirst, blurry vision, weakness, dry mouth, headaches, and frequent urination, according to the Centers for Disease Control and Prevention. What To Know The device affected by the urgent correction is the following: t:slim X2 insulin pumps. As of August 12, there had been 700 confirmed adverse events - incidents of confirmed high blood sugar or an event requiring medical intervention - and 59 reported injuries related to the device error, according to the FDA. No deaths had been reported. The FDA said that notices were sent directly to customers across the U.S. between July 22 and 24 with instructions on what to do in the event of a Malfunction 16 alarm. The company is set to release a software update to boost early detection of speaker failures, according to the FDA. The update will also introduce persistent vibration alerts to reduce potential safety risks. What People Are Saying Tandem Diabetes Care, Inc. said in its urgent medical device correction notice: "A Malfunction 16 will stop insulin delivery and terminate communication between the insulin pump and the CGM device, as well as the Tandem t:slim mobile app. If not addressed, this could result in hyperglycemia due to the malfunction resulting in the stoppage of insulin delivery and real time CGM Estimated Glucose Values (EGVs) and CGM trends. In severe cases of hyperglycemia, the user may require hospitalization or intervention from a medical professional. "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax." What Happens Next The company will notify affected pump users when the software update is available and request that the update is completed. Users who have concerns about their pumps can contact the company on techsupport@ or call 1-877-801-6901.
Newsweek
an hour ago
- Newsweek
Taiwan Plans More Cash Handouts To Boost Declining Birth Rate
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Taiwan's government plans to expand subsidies for in vitro fertilization (IVF) in hopes of raising the island democracy's birth rate, which is among the world's lowest. Why It Matters Roughly two-thirds of the world's population now live in places where fertility—births expected per woman—is below the 2.1 replacement level, according to the French Institute for Demographic Studies, as lifespans lengthen and the cost of living rises. In 2024, Taiwan recorded about 135,000 births—a record low and the ninth straight annual decline—as more couples delay or forgo children. The island also joined South Korea and Japan as a "super-aged society," with people aged 65 and older comprising about 20 percent of the population. Officials warn of the long-term economic impact of these demographic trends, but some say much more needs to be done. Newsweek reached out to Taiwan's National Development Council via written request for comment. What To Know Taiwan's Health Promotion Administration (HPA) is planning to implement higher subsidies for IVF to ease the financial burden on prospective parents. IVF is the process in which eggs are fertilized with sperm outside the body and then implanted in the uterus to achieve pregnancy. Under the subsidy program introduced in 2021, eligible couples can receive up to NT$100,000 ($3,340) for the first IVF cycle and NT$60,000 for subsequent treatments. A dog looks on from a stroller as people walk past the National Theater in front of the Chiang Kai-shek Memorial Hall in Taipei on April 5, 2023. A dog looks on from a stroller as people walk past the National Theater in front of the Chiang Kai-shek Memorial Hall in Taipei on April 5, 2023. Sam Yeh/AFP via Getty Images Most patients require three to four IVF cycles to achieve pregnancy, with cumulative chances of success rising across repeated attempts. Under the proposed increase, subsidies for treatments two to six would be brought up to the first-cycle level, HPA Director-General Shen Ching-fen told reporters Tuesday, per Taiwan's Central News Agency. As in many countries, the age at marriage and at first birth has crept upward in Taiwan, and the likelihood of pregnancy rapidly declines for women aged over 35. HPA data from 2022 show a per-cycle pregnancy rate—the probability that a single IVF cycle results in pregnancy—of about 32.6 percent at age 30, falling to about 19 percent at age 40. What People Have Said Chen Shih-cheng, former health minister and now a minister without portfolio at Taiwan's executive branch, the Executive Yuan, warned in a May article for CommonWealth Magazine that Taiwan's pro-natal measures are insufficient and investments lag behind countries like Japan and France. He called for swift action, or "it will be too late." "Both international research and local experience show that cash subsidies are not ineffective—but they are insufficient," he said. "The government may believe it is offering adequate support, but many families still face heavy financial burdens. Policy must evolve from easing the burden, to eliminating it—or even reversing it." What's Next The HPA said additional details would be announced after the subsidy scheme is approved.
